Research programme: aggrecanase inhibitors - Bristol-Myers Squibb
Alternative Names: Aggrecanase inhibitors research programme - Bristol-Myers SquibbLatest Information Update: 18 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class
- Mechanism of Action Aggrecanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 07 Aug 2006 No development reported - Preclinical for Osteoarthritis in USA (unspecified route)
- 09 Oct 2001 DuPont Pharmaceuticals has been acquired by Bristol-Myers Squibb
- 18 Sep 2000 Preclinical development for Osteoarthritis in USA (Unknown route)